350 Seventh Avenue, Suite 601
12 articles with CHDI, Inc.
EVOTEC CONFIRM CLOSING OF TRANSACTION WITH SANOFI TO ACCELERATE INFECTIOUS DISEASE RESEARCH AND DEVELOPMENT
Evotec AG today announced that the strategic transaction to integrate Sanofi's infectious disease unit including licensing-in the majority of Sanofi's infectious disease research portfolio, has been successfully closed with effect from 01 July 2018.
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
Stem Cell Sciences plc Enters into Services Agreement with Huntingdon's Disease Research Group, CHDI Foundation Inc.
Vertex Pharmaceuticals Incorporated Establishes Early-Stage Huntington’s Disease Research Collaboration with CHDI, Inc.
Huntington Disease Foundation to Assess Six of CHDI, Inc.'s Drugs for Potential to Delay or Slow Progression of the Disease
Serenex and CHDI, Inc. Form Agreement to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Huntington's Disease
CHDI, Inc. Selects Evotec As Strategic Drug Discovery Partner In The Search For Huntington Disease Treatments
CHDI, Inc. And Edison Pharmaceuticals, Inc. Enter Collaborative Agreement; Development Of Therapeutics Targeting Huntington's Disease
Cellumen, Inc. And CHDI, Inc. Announce An Agreement To Create A Systems Cell Biology Profile Of Huntington's Disease